The portal for rare diseases and orphan drugs

ABSTRACT

Orphan drugs are the stepchildren of the pharmaceutical industry. These medicinal products that are used primarily for the prevention or treatment of life‑threatening or debilitating rare diseases have restricted markets and thus limited profitability. As a consequence, the pharmaceutical industry has little interest in developing and marketing these drugs which are intended for patients who suffer from rare conditions.

KEYWORDS

• Webwise

Showing references and in-text citations exactly as published.

RELATED ARTICLES

Matched on section and article type within this issue of JPP.

• Article · VOLUME 4, ISSUE 2Evaluation of acute physiological and molecular alterations in surgically developed hypothyroid Wistar ratsMaulik Patel, Vinay Mishra, Vaibhavi Pawar, Ramchandran Ranvir, Rajesh Sundar, Rajas Dabhi · pp. 87–93Same type: Article
• Article · VOLUME 4, ISSUE 2Adverse drug reactions in the elderlyDhriti K. Brahma, Julie B. Wahlang, Maxilline D. Marak, Marlina Ch. Sangma · pp. 91–92Same type: Article
• Article · VOLUME 4, ISSUE 2Insufficient stocking of cyanide antidotes in US hospitals that provide emergency careLucas Gasco, Margaret B. Rosbolt, Vikhyat S. Bebarta · pp. 95–102Same type: Article
• Article · VOLUME 4, ISSUE 2Modulation of multidrug resistance 1 expression and function in retinoblastoma cells by curcuminSeethalakshmi Sreenivasan, Sathyabaarathi Ravichandran, Umashankar Vetrivel · pp. 103–109Same type: Article